What They Do
PBF develops medical, diagnostic, preventive, and anti-aging products, leveraging PIC/S GMP manufacturing and new drug expertise to transform research into commercially viable biotech innovations.
Value Creation
Specific value-creation activities are selectively disclosed in alignment with company and partner confidentiality.
Milestones & Achievements
2025 — Received European approval expanding Nephoxil products to dual indications (IDA + CKD).
2025 — Submitted NDA for PBF-1681 to Taiwan TFDA for iron deficiency anemia in CKD.
2023 — Strengthened PIC/S GMP manufacturing to support multi-region regulatory compliance.
2021 — Advanced next-generation ferric-citrate formulations, expanding indications beyond hyperphosphatemia.
2020 — Continued global commercialization of Nephoxil®, reinforcing pipeline reinvestment.
